Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Operating Leases (2019 - 2025)

Moleculin Biotech (MBRX) has 7 years of Operating Leases data on record, last reported at $258000.0 in Q3 2025.

  • For Q3 2025, Operating Leases fell 33.85% year-over-year to $258000.0; the TTM value through Sep 2025 reached $258000.0, down 33.85%, while the annual FY2024 figure was $358000.0, 24.47% down from the prior year.
  • Operating Leases reached $258000.0 in Q3 2025 per MBRX's latest filing, down from $292000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $496000.0 in Q3 2023 and bottomed at $50000.0 in Q1 2022.
  • Average Operating Leases over 5 years is $292631.6, with a median of $326000.0 recorded in 2025.
  • Peak YoY movement for Operating Leases: plummeted 75.33% in 2021, then surged 516.0% in 2023.
  • A 5-year view of Operating Leases shows it stood at $63000.0 in 2021, then soared by 431.75% to $335000.0 in 2022, then surged by 41.49% to $474000.0 in 2023, then decreased by 24.47% to $358000.0 in 2024, then decreased by 27.93% to $258000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $258000.0 in Q3 2025, $292000.0 in Q2 2025, and $326000.0 in Q1 2025.